Low production of reactive oxygen species and high DNA repair: Mechanism of radioresistance of prostate cancer stem cells

Anticancer Research

Volumn 33, Issue 10, 2013, Pages 4469-4474

  Kim, Young Seok ^a   Kang, Mun Jung ^a   Cho, Yong Mee ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

DNA repair; Neoplastic stem cells; Prostatic neoplasms; Radioresistance; Radiotherapy; Reactive oxygen species

Indexed keywords

CD133 ANTIGEN; DNA; GAMMA HISTONE H2AX; HISTONE H2AX; KU ANTIGEN; KU80 PROTEIN; PROTEIN; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ADHERENT CELL; ARTICLE; CANCER CELL; CANCER STEM CELL; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL DAMAGE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DNA REPAIR; ENZYME SYNTHESIS; IONIZING RADIATION; MITOSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATOSPHERE; PROTEIN EXPRESSION; RADIOSENSITIVITY;

DNA REPAIR; NEOPLASTIC STEM CELLS; PROSTATIC NEOPLASMS; RADIORESISTANCE; RADIOTHERAPY; REACTIVE OXYGEN SPECIES;

ANTIGENS, NUCLEAR; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SHAPE; DNA REPAIR; DNA-BINDING PROTEINS; HISTONES; HUMANS; MALE; NEOPLASTIC STEM CELLS; PROSTATIC NEOPLASMS; RADIATION TOLERANCE; REACTIVE OXYGEN SPECIES; SPHEROIDS, CELLULAR;

EID: 84891367550     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Nguyen PL, D'Amico AV, Lee AK and Suh WW: Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer 110(7): 1417-1428, 2007.
2. + breast cancer-initiating cells to radiation. J Natl Cancer Inst 98(24): 1777-1785, 2006.
3. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444(7120): 756-760, 2006.
4. + sector is enlarged by hypoxia. Int J Radiat Oncol Biol Phys 67(1): 1-5, 2007.
5. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL and Wahl GM: Cancer stem cells - perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 66(19): 9339-9344, 2006.
6. Ward RJ and Dirks PB: Cancer stem cells: At the headwaters of tumor development. Annu Rev Pathol 2: 175-189, 2007.
7. + prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 25(12): 1696-1708, 2006.
8. - prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer 98(4): 756-765, 2008.
9. Bisson I and Prowse DM: WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res 19(6): 683-697, 2009.
10. Mahaney BL, Meek K and Lees-Miller SP: Repair of ionizing radiation-induced DNA double-strand breaks by non-homologous end-joining. Biochem J 417(3): 639-650, 2009.
11. Alper T and Howard-Flanders P: Role of oxygen in modifying the radiosensitivity of E. coli B. Nature 178(4540): 978-979, 1956.
12. Sinclair WK: Cyclic x-ray responses in mammalian cells in vitro. Radiat Res 33(3): 620-643, 1968.
13. Cho YM, Kim YS, Kang MJ, Farrar WL and Hurt EM: Long-term recovery of irradiated prostate cancer increases cancer stem cells. Prostate 72(16): 1746-1756, 2012.
14. Kim K, Park BH, Ihm H, Kim KM, Jeong J, Chang JW and Cho YM: Expression of stem cell marker CD133 in fetal and adult human kidneys and pauci-immune crescentic glomerulonephritis. Histol Histopathol 26(2): 223-232, 2011.
15. Moncharmont C, Levy A, Gilormini M, Bertrand G, Chargari C, Alphonse G, Ardail D, Rodriguez-Lafrasse C and Magne N: Targeting a cornerstone of radiation resistance: Cancer stem cell. Cancer Lett 322(2): 139-147, 2012.
16. Pajonk F, Vlashi E and McBride WH: Radiation resistance of cancer stem cells: The 4 R's of radiobiology revisited. Stem Cells 28(4): 639-648, 2010.
17. Trachootham D, Alexandre J and Huang P: Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach? Nat Rev Drug Discov 8(7): 579-591, 2009.
18. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, Joshua B, Kaplan MJ, Wapnir I, Dirbas FM, Somlo G, Garberoglio C, Paz B, Shen J, Lau SK, Quake SR, Brown JM, Weissman IL and Clarke MF: Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458(7239): 780-783, 2009.
19. - and thereby promotes tumor growth. Cancer Cell 19(3): 387-400, 2011.
20. Herault O, Hope KJ, Deneault E, Mayotte N, Chagraoui J, Wilhelm BT, Cellot S, Sauvageau M, Andrade-Navarro MA, Hebert J and Sauvageau G: A role for GPx3 in activity of normal and leukemia stem cells. J Exp Med 209(5): 895-901, 2012.
21. Zhang M, Atkinson RL and Rosen JM: Selective targeting of radiation-resistant tumor-initiating cells. Proc Natl Acad Sci USA 107(8): 3522-3527, 2010.
22. Maugeri-Sacca M, Bartucci M and De Maria R: DNA damage repair pathways in cancer stem cells. Mol Cancer Ther 11(8): 1627-1636, 2012.
23. Ginjala V, Nacerddine K, Kulkarni A, Oza J, Hill SJ, Yao M, Citterio E, van Lohuizen M and Ganesan S: BMI1 is recruited to DNA breaks and contributes to DNA damage-induced H2A ubiquitination and repair. Mol Cell Biol 31(10): 1972-1982, 2011.
24. Facchino S, Abdouh M, Chatoo W and Bernier G: BMI1 confers radioresistance to normal and cancerous neural stem cells through recruitment of the DNA damage response machinery. J Neurosci 30(30): 10096-10111, 2010.
25. Lukacs RU, Memarzadeh S, Wu H and Witte ON: Bmi-1 is a crucial regulator of prostate stem cell self-renewal and malignant transformation. Cell Stem Cell 7(6): 682-693, 2010.
26. Visvader JE and Lindeman GJ: Cancer stem cells: Current status and evolving complexities. Cell Stem Cell 10(6): 717-728, 2012.
27. Bubendorf L, Sauter G, Moch H, Schmid HP, Gasser TC, Jordan P and Mihatsch MJ: Ki-67 labelling index: An independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol 178(4): 437-441, 1996.
28. May M, Siegsmund M, Hammermann F, Loy V and Gunia S: Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy. Scand J Urol Nephrol 41(5): 375-381, 2007.
29. Rockwell S: In vivo-in vitro tumour cell lines: Characteristics and limitations as models for human cancer. Br J Cancer Suppl 4: 118-122, 1980.
30. Pinski J, Parikh A, Bova GS and Isaacs JT: Therapeutic implications of enhanced G(0)/G(1) checkpoint control induced by coculture of prostate cancer cells with osteoblasts. Cancer Res 61(17): 6372-6376, 2001.